Effectiveness and cost analysis of liposomal irinotecan in patients with pancreatic adenocarcinoma: a multicenter real-world study.

ABSTRACT:

Background

Systemic chemotherapy is crucial for pancreatic adenocarcinoma (PAC). It serves as a palliative chemotherapy for unresectable PAC and as a (neo-)adjuvant chemotherapy for (borderline) resectable PAC. Survival benefits were found with the use of liposomal irinotecan combined with 5-fluorouracil and leucovorin (nal-IRI/5-FU/LV) in the global phase III NAPOLI-1 trial. However, limited evidence supports the cost-effectiveness of liposomal irinotecan throughout the PAC treatment course.

Objectives

We investigated the real-world efficacy and cost implications of nal-IRI/5-FU/LV in PAC management.

Design

A multicenter real-world study.

Methods

We analyzed real-world data from electronic health records to evaluate outcomes of nal-IRI/5-FU/LV exposure in this

SUBMITTER: Chun JW 

PROVIDER: S-EPMC12433562 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature